BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access
(Financial Post, 2025-10-13T10:04:36Z)